GlycoVaxyn and a Harvard University affiliated hospital receive USD 3.4 million NIH grant for Staphylococcus aureus vaccine
Advertisement
GlycoVaxyn AG and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women’s Hospital, Harvard Medical School, announced that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine.
Using GlycoVaxyn’s proprietary technology, staphylococcal surface polysaccharides will be conjugated in vivo to conserved protein antigens from S. aureus. The efficacy of this novel bioconjugate vaccine will then be evaluated in different animal models of S. aureus infection.
“GlycoVaxyn’s first generation S. aureus bioconjugate vaccine has shown protective efficacy in preclinical studies. The new generation vaccine is expected to give broader protection against a variety of S. aureus strains,” declared Dr. Jean Lee.
GlycoVaxyn and the Brigham and Women’s Hospital have a long standing collaboration on this project, and the NIH funding will accelerate the development of potential vaccine candidates.
GlycoVaxyn, which started Phase I clinical trials with a bioconjugate vaccine against Shigella dysenteriae early this year, is expecting to start a clinical trial with its first generation S. aureus vaccine by late 2011.
“Our bioconjugation technology allows us a very flexible and powerful approach to multivalent vaccine development, coupling polysaccharide to protein antigens in a strictly controlled way,” said Dr. Michael Wacker, CSO and founder of GlycoVaxyn. “This grant confirms the potential of this approach and will allow extensive preclinical evaluation of the novel vaccine.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Novozymes Biopharma secures CPhI 2009 innovation award for its albufuse technology
Antisense Pharma Granted Patents on Medical Device for Application of Neurotherapeutics
Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials
EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs